linolenic acid; ARB: angiotensin II receptor blocker; ASA: acetylsalicylic acid; .... Albert BB, Derraik JG, Brennan CM, Biggs JB, Smith GC, Garg ML, et al.
Poreba et al. Cardiovasc Diabetol (2018) 17:29 https://doi.org/10.1186/s12933-018-0672-5
Cardiovascular Diabetology
ORIGINAL INVESTIGATION
Open Access
Relationship between polyunsaturated fatty acid composition in serum phospholipids, systemic low‑grade inflammation, and glycemic control in patients with type 2 diabetes and atherosclerotic cardiovascular disease Malgorzata Poreba1†, Pawel Rostoff1†, Aleksander Siniarski1, Magdalena Mostowik1, Renata Golebiowska‑Wiatrak1, Jadwiga Nessler1, Anetta Undas2 and Grzegorz Gajos1*
Abstract Background: There are inconsistent data about the role of serum phospholipid fatty acid composition in patients with type 2 diabetes (T2DM) and atherosclerotic cardiovascular disease (ASCVD). The aim of the study was to inves‑ tigate the relationship between serum phospholipid fatty acid composition, systemic low-grade inflammation, and glycemic control in high-risk T2DM patients. Methods: Seventy-four patients (26% women, mean age 65.6 ± 6.8 years) with T2DM (median diabetes duration 10 years) and documented ASCVD (74 with coronary artery disease, 26 with peripheral arterial disease) were enrolled in the study. Baseline HbA1c was estimated using turbidimetric inhibition immunoassay. According to the median value of HbA1c the patients were grouped into those with HbA1c
